Regeneron Pharmaceuticals started the final stage of clinical trials of REGN-COV2 for the treatment and prevention of COVID-19. Phase 3 of the study will assess the ability of REGN-COV2 to prevent the occurrence of COVID-19 in uninfected people. The trials will be conducted jointly with the National Allergy Institute and will cover 2,000 patients in the United States.
Regeneron Pharmaceuticals started the final stage of clinical trials of REGN-COV2 for the treatment and prevention of COVID-19. Phase 3 of the study will assess the ability of REGN-COV2 to prevent the occurrence of COVID-19 in uninfected people. The trials will be conducted jointly with the National Allergy Institute and will cover 2,000 patients in the United States. 
investor.regeneron.com
English (US) 